A new patent for Concert Pharmaceuticals here, Deuterated Ibrutinib. Ibrutinib is sold commercially under the name Imbruvica, and has a 50% - 50% sales sharing agreement by AbbVie and JNJ. Imbruvica is a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and is dosed once daily. The patent expiration date is July 2032, for d-ibrutinib, and 2026 at the earliest for the non-deuterated ibrutinib.
The drug is going head to head against Astra Zeneca's ACP-196, in a clinical trial below for previously treated subjects, with high risk chronic lymphocytic leukemia.
Bottom Line: Analyst have projected up to 6 billion in annual revenue for Imbruvica, for various cancer indications. The 500 patient head to head clinical trial against ACP-196 above will not readout until 2019, but more importantly when complete, will display a safety and efficacy comparison for these two drugs. Thank you for reading.
The drug is going head to head against Astra Zeneca's ACP-196, in a clinical trial below for previously treated subjects, with high risk chronic lymphocytic leukemia.
| Estimated Enrollment: | 500 |
| Study Start Date: | June 2015 |
| Estimated Primary Completion Date: | June 2019 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: ACP-196
ACP-196 will be orally administered until disease progression or unacceptable toxicity.
| Drug: ACP-196 |
| Active Comparator: ibrutinib
Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
| Drug: ibrutinib |
Bottom Line: Analyst have projected up to 6 billion in annual revenue for Imbruvica, for various cancer indications. The 500 patient head to head clinical trial against ACP-196 above will not readout until 2019, but more importantly when complete, will display a safety and efficacy comparison for these two drugs. Thank you for reading.
No comments:
Post a Comment